What did @landotalkspeps actually say?
The creator recommended three peptides to stack with semaglutide (referred to as "Retta," likely Wegovy/Ozempic): tesamorelin (called "Tessa Morro"), GHK-Cu, and MOTS-c (called "MOTC"). The core claims are that tesamorelin targets visceral fat through growth hormone pathways, GHK-Cu tightens loose skin caused by rapid weight loss, and MOTS-c improves energy efficiency, fat burning, and insulin sensitivity. These are specific, mechanistic claims, not vague wellness talk, which makes them worth examining carefully.
To be clear about terminology: "Retta" appears to refer to a GLP-1 receptor agonist like semaglutide. The creator is describing a multi-peptide stack layered on top of an already powerful weight-loss drug. That context matters when evaluating both the science and the safety picture.
Does the science back this up?
Partially, but the evidence quality varies wildly across these three compounds. Tesamorelin has the strongest human trial data of the bunch. GHK-Cu has plausible mechanisms but thin clinical evidence. MOTS-c is genuinely interesting but almost entirely preclinical at this point.
Tesamorelin is FDA-approved for HIV-associated lipodystrophy specifically because it reduces visceral adipose tissue. Falutz et al. (2007, New England Journal of Medicine) showed statistically significant visceral fat reduction versus placebo. The claim that it works "through growth hormone pathways" is accurate, it stimulates GHRH receptors. However, calling it a clean stack with a GLP-1 agonist for general weight loss oversimplifies things. Tesamorelin's approval is narrow, and its use outside that indication is off-label with limited safety data in combination with semaglutide.
GHK-Cu is a copper-binding tripeptide with published in vitro work on collagen synthesis and skin remodeling. Pickart and Margolina (2018, Cosmetics) reviewed its skin-related properties, but the gap between cell culture data and clinical skin tightening after GLP-1-induced weight loss is enormous. No trials have tested this specific use case.
MOTS-c is a mitochondrial-derived peptide. Lee et al. (2015, Cell Metabolism) showed metabolic benefits in mice, including improved insulin sensitivity. Human data is scarce and preliminary. The creator's confidence in MOTS-c outpaces the evidence significantly.
What did they get wrong (or right)?
They got the tesamorelin mechanism mostly right. They got MOTS-c mostly wrong by how confidently they stated it. The GHK-Cu skin claim is speculative at best.
Credit where it is due: the statement that tesamorelin signals "your pituitary to release more of its own natural growth hormone" is a reasonable lay explanation of GHRH receptor agonism, though technically tesamorelin acts on the hypothalamic-pituitary axis rather than directly on the pituitary. The framing that it "directly targets visceral fat" aligns with the mechanism seen in Falutz et al., so that part holds up.
The GHK-Cu claim that it will "tighten your skin up" after body recomposition is the weakest link here. Cosmetic in vitro data does not translate into a clinical promise about loose skin after significant weight loss. That is a very specific outcome with no clinical trial support in this population.
MOTS-c described as something that lets you "use your energy more efficiently" and "increase the fat you burn" is largely extrapolated from rodent studies. Presenting this as established for humans is misleading, even if the underlying biology is plausible.
What should you actually know?
Stacking multiple peptides with a GLP-1 agonist is not a small decision, and the evidence base for these combinations is essentially nonexistent. No clinical trial has evaluated tesamorelin plus semaglutide, let alone a three-way stack that includes GHK-Cu and MOTS-c.
Tesamorelin has real clinical data behind it, but it is a prescription peptide with a narrow FDA-approved use. GHK-Cu has a reasonable safety profile topically but its systemic injectable use lacks rigorous human data. MOTS-c is not approved for any use and has no meaningful human pharmacokinetic or safety data published as of 2024.
There is also a compounding quality issue worth naming. Many peptides circulating in the optimization space come from compounding pharmacies or gray-market sources. Purity, dosing accuracy, and sterility are not guaranteed. The FDA has raised concerns specifically about compounded peptides.
- If you are on a GLP-1 agonist and considering peptide add-ons, talk to a physician who understands both the pharmacology and your specific health context.
- Do not assume that because something works in a mouse model or an in vitro study, it will work the same way in a human body already on a GLP-1 drug.
- Peptides like tesamorelin require a prescription and legitimate clinical oversight, not a TikTok stack recommendation.